With cash reserves dwindling, Oxurion plans early DME trial readout

News
Genetic testing hopes to speed up drug development in rare eye diseases

Oxurion will carry out an interim analysis of a phase 2 trial of its last remaining clinical asset – THR-149 for diabetic macular oedema (DME) – before the end of this year as it tries to get an early take on its efficacy.

With top-line results from the KALAHARI trial not due until the second half of 2023 – and cash reserves dwindling – the Belgian biotech hopes to look at the data after at least 25% of patients in the phase 2b portion of the study is completed.

Oxurion ended 2021 with €10 million in available cash, according to its annual report, and added to that total by raising another €10 million in a private placement that closed in March. The company was rocked in May by the failure of another candidate for DME in a phase 2 trial, forcing it to throw all its resources behind THR-149.

By the end of June, cash reserves had fallen to just over €3.7 million, and Oxurion indicated at that time that it did not have enough working capital for the following 12 months – a period which would come to an end before the KALAHARI readout.

That means it will have to raise additional funding or face the prospect of being unable to continue operations. A positive readout for THR-149 could make it easier to raise more capital from investors, or potentially license out the drug to another company.

THR-149 is a plasma kallikrein (PKal) inhibitor that Oxurion is hoping to position as a treatment for DME patients who do not respond to treatment with blockbuster anti-VEGF drugs like Bayer/Regeneron's Eylea (aflibercept) and Roche/Novartis' Lucentis (ranibizumab) – a group that represents up to 50% of all patients with the sight-robbing condition.

The KALAHARI trial has two parts, with the first dose-ranging stage showing that the drug was able to improve Best-Corrected Visual Acuity (BCVA) scores in patients who had failed to respond adequately to anti-VEGF therapy at the highest dose tested.

That dose – three monthly injections into the eye of 0.13 mg THR-149 – achieved a 6.1-point improvement in BCVA over baseline, which increased two 9 points if two patients who were considered be unsuitable candidates for treatment due to abnormalities were excluded.

Meanwhile, THR-149 was also able to stabilise central subfield thickness (CST) – which deteriorates in DME – for at least six months. The second stage of the study is comparing THR-149, Eylea, and a combination of the two drugs.

Last year, the Belgian company narrowed its focus to the two DME projects in order to conserve cash, halting investment in an oncology spinout – Oncurious – and putting some other R&D projects on hold.

The biotech is facing some big-name competition in DME, however, including from Roche, whose bispecific antibody Vabysmo (faricimab) targeting VEGF and Ang-2 was recently approved by the FDA.